Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Headache, Injection site discolouration, Injection site warmth, Vaccination site erythema
Clinical narrative: pink injection site(look improved); tender and hot to the touch (Temperature on injection site: 100.4F vs. the other areas was 96F); Injection site had a large rash 5X5" (Soft Ball Size); red injection site; itchy injection iste; secondary swollen ate injection site; Headache (vaccine made the Migraine more prevalent); Injection site hurt; Injection Site was Swollen; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (Headache (vaccine made the Migraine more prevalent)), INJECTION SITE WARMTH (tender and hot to the touch (Temperature on injection site: 100.4F vs. the other areas was 96F)), VACCINATION SITE PAIN (Injection site hurt), VACCINATION SITE SWELLING (Injection Site was Swollen) and VACCINATION SITE RASH (Injection site had a large rash 5X5" (Soft Ball Size)) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 1152) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Migraine (but vaccine made the Migraine more prevalent).    On 21-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 21-Jan-2021, the patient experienced VACCINATION SITE PAIN (Injection site hurt) and VACCINATION SITE SWELLING (Injection Site was Swollen). On 25-Jan-2021, the patient experienced HEADACHE (Headache (vaccine made the Migraine more prevalent)). On 29-Jan-2021, the patient experienced INJECTION SITE WARMTH (tender and hot to the touch (Temperature on injection site: 100.4F vs. the other areas was 96F)), VACCINATION SITE RASH (Injection site had a large rash 5X5" (Soft Ball Size)), VACCINATION SITE ERYTHEMA (red injection site), VACCINATION SITE PRURITUS (itchy injection iste) and VACCINATION SITE SWELLING (secondary swollen ate injection site). On 02-Feb-2021, the patient experienced INJECTION SITE DISCOLOURATION (pink injection site(look improved)). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Itching, at an unspecified dose and frequency and SUMATRIPTAN (IMITREX [SUMATRIPTAN]) for Headache, at an unspecified dose and frequency. On 23-Jan-2021, VACCINATION SITE PAIN (Injection site hurt) and VACCINATION SITE SWELLING (Injection Site was Swollen) had resolved. On 26-Jan-2021, HEADACHE (Headache (vaccine made the Migraine more prevalent)) had resolved. On 01-Feb-2021, INJECTION SITE WARMTH (tender and hot to the touch (Temperature on injection site: 100.4F vs. the other areas was 96F)), VACCINATION SITE RASH (Injection site had a large rash 5X5" (Soft Ball Size)), VACCINATION SITE ERYTHEMA (red injection site), VACCINATION SITE PRURITUS (itchy injection iste) and VACCINATION SITE SWELLING (secondary swollen ate injection site) had resolved. At the time of the report, INJECTION SITE DISCOLOURATION (pink injection site(look improved)) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 100.4 Farad (High) at injection site and 96 Farad (Inconclusive) other areas of body.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 21-Apr-2021: TCR form is received states that consumer declined further fu